Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Change in Cash (2016 - 2025)

IGC Pharma (IGC) has disclosed Change in Cash for 16 consecutive years, with $651000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Cash rose 334.17% to $651000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$441000.0, a 70.2% increase, with the full-year FY2025 number at -$793000.0, up 60.31% from a year prior.
  • Change in Cash was $651000.0 for Q3 2025 at IGC Pharma, up from $49000.0 in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $13.6 million in Q1 2021 to a low of -$2.5 million in Q4 2021.
  • A 5-year average of $7210.5 and a median of -$1.1 million in 2024 define the central range for Change in Cash.
  • Biggest YoY gain for Change in Cash was 573.01% in 2021; the steepest drop was 1243.17% in 2021.
  • IGC Pharma's Change in Cash stood at -$2.5 million in 2021, then surged by 31.73% to -$1.7 million in 2022, then grew by 1.79% to -$1.6 million in 2023, then soared by 34.71% to -$1.1 million in 2024, then skyrocketed by 160.5% to $651000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Change in Cash are $651000.0 (Q3 2025), $49000.0 (Q2 2025), and -$65000.0 (Q1 2025).